, , ,

<<


 >>  ()
Pages:     | 1 |   ...   | 8 | 9 || 11 |

...

-- [ 10 ] --

492. Holtzer CD, Jacobson MA, Hadley WK, et al. Decline in the rate of specific opportunistic infections at San Francisco General Hospital, 19941997. AIDS. 1998;

12:19311933.

493. Holtzman DM, Kaku DA, So YT. New-onset seizures associated with human immunodeficiency virus infection: Causation and clinical features in 100 cases. Am J Med. 1989;

87:173177.

494. Homsy J, Meyer M, Levy JA. Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals. J Virol. 1990;

64:14371440.

495. Honda Y, Rogers L, Nakata K, et al. Type I interferon induces inhibitory 16-kD CCAAT/enhancer binding protein (C/EBP) beta, repressing the HIV-1 long terminal repeat in macrophages: Pulmonary tuberculosis alters C/EBP expression, enhancing HIV-1 replication. J Exp Med. 1998;

188: 496. Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000;

32:635-9.

497. Hook E, et al. Herpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals. J Infect Dis. 1992;

165:251.

498. Hoover R, Fraumeni J. Risk of cancer in renal transplant recipients. Lancet. 1973;

2:5557.

499. Horsburgh CR Jr, Ou CY, Jason J, et al. Duration of human immunodeficiency virus infection before detection of antibody. Lancet. 1989;

2:637640.

500. Hosmalin A, Clerici M, Houghten R, et al. An epitope in human immunodeficiency virus 1 reverse transcriptase recognized by both mouse and human cytotoxic T lymphocytes. Proc Natl Acad Sci U S A. 1990;

87:23442348.

501. Howcroft T, Strebel K, Martin M, et al. Repression of MHC class I gene promoter activity by two-exon tat of HIV. Science. 1993;

260:13201322.

502. Hsia K, Tsai V, Zvaifler NJ, et al. Low prevalence of HIV-1 proviral DNA in peripheral blood monocytes and dendritic cells from HIV-1infected individuals. AIDS. 1995;

9:398399.

503. Hsieh CS, Macatonia SE, Tripp CS, et al. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science. 1993;

260:547 504. Hu DJ, Heyward WL, Byers RH Jr, et al. HIV infection and breastfeeding: Policy implications through a decision analysis model. AIDS. 1992;

6:15051513.

505. Hu PF, Hultin LE, Hultin P, et al. Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a population of CD16dimCD56- cells with low lytic activity. J Acquir Immune Defic Syndr Hum Retrovirol.

1995;

10:331340.

506. Huang Y, Paxton W, Wolinsky S, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med. 1996;

2:12401243.

507. Huang Y, Zhang L, Ho D. Biological characterization of nef in long term survivors of human immunodeficiency virus type 1 infection. J Virol. 1995;

69:81428146.

508. Huang Y, Zhang L, Ho DD. Characterization of nef sequences in long-term survivors of human immunodeficiency virus type 1 infection. J Virol. 1995;

69:93100.

509. Humphrey RW, O'Brien TR, Newcomb FM, et al. Kaposi's sarcoma (KS)associated herpesvirus-like KNA sequences in peripheral blood mononuclear cells: Association with KS and pesistence in patients receiving anti-herpesvirus drugs. Blood. 1996;

88:297301.

510. Hutto C, Parks WP, Lai S, et al. A hospital-based prospective study of perinatal infection with human immunodeficiency virus type 1. J Pediatr. 1991;

118:347353.

511. Imberti L, Sottini A, Bettinardi A, et al. Selective depletion in HIV infection of T cells that bear specific T cell receptor V beta sequences. Science. 1991;

254: 860862.

512. Ioachim HL, Lerner CW, Tapper ML. The lymphoid lesions associated with the acquired immunodeficiency syndrome. Am J Surg Pathol. 1983;

7:543553.

513. Ippolito G, Puro V, De Carli G. The risk of occupational human immunodeficiency virus infection in health care workers. Italian multicenter study. Arch Intern Med. 1993;

153:14511458.

514. Irwin, K., N. Olivo, and C.A. Schable et al. 1996. Performance characteristics of a rapid HIV antibody assay in a hospital with a high prevalence of HIV infection. Ann Intern Med 125:471-475.

515. Israelski DM, Chmiel JS, Poggenser L, et al. Prevalence of Toxoplasma infection in a cohort of homosexual men at risk of AIDS and toxoplasmic encephalitis. J Acquir Immune Defic Syndr.

1993;

6:414418.

516. Iversen AKN, Shpaer EG, Rodrigo AG, et al. Persistence of attenuated rev genes in a human immunodeficiency virus type 1infected asymptomatic individual. J Virol. 1995;

69:57435753.

517. Jackson JB, Drew J, Lin HJ, et al. Establishment of a quality assurance program for human immunodeficiency virus type 1 DNA polymerase chain reaction assays by the AIDS Clinical Trials Group. ACTG PCR Working Group, and the ACTG PCR Virology Laboratories. J Clin Microbiol.

1993;

31:31233128.

518. Jackson JB, Mracna M, Guay L, et al. Selection of Nevirapine (NVP) resistance mutations in Ugandan women and infants receiving NVP prophylaxis to prevent HIV-1 vertical transmission (HIVNET-012).

Abstract LbOr 13, 13th International AIDS Conference 2000, Durban, South Africa.

519. Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med. 1997;

336:14871493.

520. Jacobson L. Impact of highly effective antiretroviral therapy on recent trends in cancer among HIV infected individuals. Abstract S5. Presented at the Second National AIDS Malignancy Conference, Bethesda, Md, April 68, 1998.

521. Jacobson MA. Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. N Engl J Med.1997;

337: 522. Jaffe HW, Hardy AM, Morgan WM, et al. The acquired immunodeficiency syndrome in gay men. Ann Intern Med. 1985;

103:662664.

523. Janoff EN, Breiman RF, Daley CL, et al. Pneumococcal disease during HIV infection. Ann Intern Med.

1992;

117:314324.

524. Janoff NE, Breiman RF, Daley CL, et al. Pneumococcal disease during HIV infection. Epidemiologic, clinical, and immunologic perspectives. Ann Intern Med. 1992;

117:314324.

525. Janossy G, Pinching AJ, Bofill M, et al. An immunohistological approach to persistent lymphadenopathy and its relevance to AIDS. Clin Exp Immunol. 1985;

59:257266.

526. Jarvik JG, Hesselink JR, Kennedy C, et al. Acquired immunodeficiency syndrome: Magnetic resonance patterns of brain involvement with pathologic correlation. Arch Neurol. 1998;

45:731736.

527. Javaherian K, Langlois AJ, McDanal C, et al. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci U S A. 1989;

86:67686772.

528. Jemsek J, Hutcherson P, and Harper E. Poor virologic responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco. February 8-11, 2004. Abstract 51.

529. Jemsek J, Hutcherson P, Harper E. Poor Virologic Responses and Early Emergence of Resistance in Treatment Naive, HIV-infected Patients Receiving a Once Daily Triple Nucleoside Regimen of Didanosine, Lamivudine, and Tenofovir DF. 11th Conference on Retroviruses and Opportunistic Infections;

February 8-11, 2004;

San Francisco. Abstract 51.

530. Jemsek J, Hutcherson P, Harper E. Poor virologic responses and early emergence of resistance in treatment-naive, HIV-infected patients receiving a once-daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF. 11th Conference on Retroviruses and Opportunistic Infections;

San Francisco;

February 8-11, 2004. Abstract 51.

531. Johnson AA, Ray AS, Hanes J, Suo Z, Colacino JM, Anderson KS, Johnson KA. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem 2001;

276:40847-57.

532. Johnson AM, Petherick A, Davidson SJ, et al. Transmission of HIV to heterosexual partners of infected men and women. AIDS. 1989;

3:367372.

533. Johnson AM. Condoms and HIV transmission. N Engl J Med. 1994;

331:391 534. Johnson VA, Merrill DP, Chou TC, Hirsch MS. Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2,3-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro. J Infect Dis.

1992;

166:11431146.

535. Johnson VA, Merrill DP, Videler JA, et al. Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J Infect Dis. 1991;

164:646655.

536. Joly V, Flandre P, Meiffredy V, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS, 2002. 16(18):2447-54.

537. Jones BD, Taikwel EK, Mercado AL, et al. Tuberculosis in patients with HIV infection who receive corticosteroids for presumed Pneumocystis carinii pneumonia. Am J Respir Crit Care Med.

1994;

149:16861688.

538. Jones J, Hanson D, Ward J. Effect of antiretroviral therapy on recent trends in cancer among HIV infected persons. Abstract S3. Presented at the Second National AIDS Malignancy Conference, Bethesda, Md, April 68, 1998.

539. Jost S, Bernard MC, Kaiser L, et al. HIV super-infection: rapid replacement of AE subtype by B subtype. 9th Conference on Retroviruses and Opportunistic Infections;

Washington;

2428 February, 2002.

540. Jourdain G, Ngo-Giang-Huong N, Tungyai P, et al. Exposure to Intrapartum Single-dose Nevirapine and Subsequent Maternal 6-Month Response to NNRTI-based Regimens. Abstract 41LB. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, February 8-11, 2004.) 541. Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. N Engl J Med. 1992;

327:581587.

542. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med.

1998;

339: 543. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med 1998;

339:3339.

544. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000;

22:685-708.

545. Kalayjian RC, Toossi Z, Tomashefski JF Jr, et al. Pulmonary disease due to infection by Mycobacterium avium complex in patients with AIDS. Clin Infect Dis. 1995;

20:11861194.

546. Kalyanaraman VS, Sarngadharan MG, Robert-Guroff M, et al. A new subtype of human T-cell leukaemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukaemia. Science.

1982;

218: 547. Kamenga M, Ryder RW, Jingu M, et al. Evidence of marked sexual behaviour change associated with low HIV-1 seroconversion in 149 married couples with discordant HIV-1 status: Experiences at an HIV counselling centre in The Democratic Republic of Congo. AIDS 1991;

5:6167.

548. Kane, B. Rapid testing for HIV: Why so fast? Ann Internal Med. 1999;

131: 481-483.

549. Kapiga SH, Shao JF, Lwihula GK, et al. Risk factors for HIV infection among women in Dar-es Salaam, Tanzania. J Acquir Immune Defic Syndr. 1994;

7:301309.

550. Kaplan JE, Hanson D, Jones J. Risk factors for primary PCP in HIV-infected adolescents and adults in the U.S. Should history of AIDS-defining illness be included in the criteria for PCP prophylaxis?

Abstract 290. In: Abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections, American Society of Microbiology, Washington, DC;

January 2226, 1997.

551. Kaplan JE, Hanson D, Jones J. Risk factors for primary PCP in HIV-infected adolescents and adults in the U.S. Should history of AIDS-defining illness be included in the criteria for PCP prophylaxis?

Abstract 290. In: Abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections, American Society of Microbiology, Washington, DC;

January 2226, 1997.

552. Kaplan L, Hopewell P, Jaffe H. Kaposi's sarcoma involving the lung in patients with the acquired immunodeficiency syndrome. J Acquir Immune Defic Syndr. 1988;

1:2330.

553. Kaplan L, Kahn J, Jacobson M, et al. Primary bile duct lymphoma in the acquired immmunodeficiency syndrome (AIDS). Ann Intern Med. 1989;

110:162.

554. Kaplan LD, Abrams DI, Feigal E, et al. AIDS-associated non-Hodgkin's lymphoma in San Francisco.

JAMA. 1989;

261:719 555. Kaposi M. Zur Nomenclatur des idiopathischen Pigmentsarkom Kaposi. Arch Dermatol Syph (Berl) 1894;

29:164.

556. Karhumaki E, Viljanen ME, Cottler-Fox M, et al. An improved enrichment method for functionally competent, highly purified peripheral blood dendritic cells and its application to HIV-infected blood samples. Clin Exp Immunol. 1993;

91:482488.

557. Kashuba AD, Tierney C, Downey GF, Acosta EP, Vergis EN, Klingman K, Mellors JW, Eshleman SH, Scott TR, Collier AC. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. AIDS. 2005 Jan 28;

19(2):145-52.

558. Kaslow RA, Carrington M, Apple R, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med. 1996;

2:405411.

559. Kassler WJ, Haley C, Jones WK, et al. Performance of a rapid, on-site human immunodeficiency virus antibody assay in a public health setting. J Clin Microbiol. 1995;

33:28992902.

560. Katlama C, De Wit S, O'Doherty E, et al. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis.

1996;

22: 561. Katlama C, Ingrand D, Loveday C, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. JAMA. 1996;

276:118125.

562. Katlama C, Valantin MA, Matheron S, et al. Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infection. Ann Intern Med.

1998;

129:525531.

563. Kawakami K, Scheidereit C, Roeder RG. Identification and purification of a human immunoglobulin enhancer-binding protein (NF- B) that activates transcription from a human immunodeficiency virus type 1 promoter in vitro. Proc Natl Acad Sci U S A. 1988;

85:4700.

564. Kearney BP, Isaacson E, Sayre J, et al. Didanosine and tenofovir DF drug-drug interaction: assessment of didanosine dose reduction. 10th Conference on Retroviruses and Opportunistic Infections, Seattle, February 9-14, 2002. Abstract 533.

565. Kearney BP, Isaacson E, Sayre J, et al. Didanosine and tenofovir DF drug-drug interaction: assessment of didanosine dose reduction. 10th Conference on Retroviruses and Opportunistic Infections;

February 9-14, 2002;

Seattle. Abstract 533.

566. Kedes DH, Operskalski E, Busch M, et al. The epidemiology of human herpesvirus 8 (Kaposi's sarcomaassociated herpesvirus): Distribution of infection in KS risk groups and evidence for sexual transmission. Nat Med. 1996;

2:918924.

567. Keet IP, Klein MR, Just JJ, et al. The role of host genetics in the natural history of HIV-1 infection: The needles in the haystack. AIDS. 1996;

10(Suppl A): S59S67.

568. Kehrl JH, Rieckmann P, Kozlow E, et al. Lymphokine production by B cells from normal and HIV infected individuals. Ann N Y Acad Sci. 1992;

651:220227.

569. Kelly, J.A., Murphy, D.A., Sikkema, K.J., and Kalichman, S.C. Psychological interventions to prevent HIV infection are urgently needed: new priorities for behavioral research in the second decade of AIDS.

Am. Psychol 1993;

48: 1023-1034.

570. Kemper CA, Tucker RM, Lang DS, et al. Low dose dapsone prophylaxis of Pneumocystis carinii pneumonia in AIDS and AIDS-related complex. AIDS. 1990;

4:11451148.

571. Kempf DJ, Marsh KC, Denissen JF, et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci U S A. 1995;

92:2484 2488.

572. Kennedy CA, Goetz MB. Atypical roentgenographic manifestations of Pneumocystis carinii pneumonia. Arch Intern Med. 1992;

152:1390 573. Kent SJ, Stent G, Sonza S, et al. HIV-1 infection of monocyte-derived macrophages reduces Fc and complement receptor expression. Clin Exp Immunol. 1994;

95: 450454.

574. Kerkau T, Bacik I, Bennink JR, et al. The human immunodeficiency virus type 1 (HIV-1) vpu protein interferes with an early step in the biosynthesis of major histocompatibility complex (MHC) class I molecules. J Exp Med. 1997;

185:12951305.

575. Kessler HA, Blaauw B, Spear J, et al. Diagnosis of human immunodeficiency virus infection in seronegative homosexuals presenting with an acute viral syndrome. JAMA. 1987;

258:11961199.

576. Khadir A, Coutlee F, Saint-Antoine P, et al. Clinical evaluation of Amplicor HIV-1 test for detection of human immunodeficiency virus type 1 proviral DNA in peripheral blood mononuclear cells. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;

9(3):257263.

577. Kido H, Fukutomi A, Katunuma N. A novel membrane-bound serine esterase in human T4+ lymphocytes immunologically reactive with antibody inhibiting syncytia induced by HIV-1. Purification and characterization. J Biol Chem. 1990;

265:2197921985.

578. Kieburtz K, Yiannoutsos CP, Simpson D, AIDS Clinical Trials Group. A double-blind, randomized clinical trial of amitriptyline and mexiletine for painful neuropathy in human immunodeficiency virus infection (Abstract). Ann Neurol. 1997;

42:429.

579. Kieburtz KD, Eskin TA, Ketonen L, Tuite MJ. Opportunistic cerebral vasculopathy and stroke in patients with the acquired immunodeficiency syndrome. Arch Neurol. 1993;

50:430432.

580. Kieburtz KD, Seidlin M, Lambert JS, et al. Extended follow-up of peripheral neuropathy in patients with AIDS and AIDS-related complex treated with dideoxyinosine. J Acquir Immune Defic Syndr.

1992;

5:6064.

581. Kim SY, Byrn R, Groopman J, Baltimore D. Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: Evidence for differential gene expression. J Virol.

1989;

63: 582. Kinter A, Fauci AS. Interleukin-2 and human immunodeficiency virus infection: Pathogenic mechanisms and potential for immunologic enhancement. Immunol Res. 1996;

15:115.

583. Kinter AL, Ostrowski M, Goletti D, et al. HIV replication in CD4+ T cells of HIV-infected individuals is regulated by a balance between the viral suppressive effects of endogenous beta-chemokines and the viral inductive effects of other endogenous cytokines. Proc Natl Acad Sci U S A. 1996;

93:14076 14081.

584. Kinter AL, Poli G, Fox L, et al. HIV replication in IL-2stimulated peripheral blood mononuclear cells is driven in an autocrine/paracrine manner by endogenous cytokines. J Immunol. 1995;

154:24482459.

585. Kirchhoff F, Greenough TC, Brettler DB, et al. Brief report: Absence of intact nef sequences in a long term survivor with nonprogressive HIV-1 infection. N Engl J Med. 1995;

332:228232.

586. Kirk O, Katzenstein TL, Gerstoft J, Mathiesen L, Nielsen H, Pedersen C, Lundgren JD. Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial. AIDS 1999;

13:F9-16.

587. Klatzmann D, Barre-Sinoussi F, Nugeyre MT, et al. Selective tropism of lymphadenopathy-associated virus (LAV) for helper-inducer T-lymphocytes. Science. 1984;

225:59 588. Klatzmann D, Champagne E, Chamaret S, et al. T-lymphocyte T4 molecule behaves as receptor for human retrovirus LAV. Nature. 1984;

312:767 589. Klein MR, Keet IPM, D'Amaro J, et al. Associations between HLA frequencies and pathogenic features of human immunodeficiency virus type 1 infection in seroconverters from the Amsterdam Cohort of Homosexual Men. J Infect Dis. 1994;

169:12441249.

590. Klein MR, vanBaalen CA, Holwerda AM, et al. Kinetics of gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med. 1995;

181:13651372.

591. Klein RS, Harris CA, Small CB, et al. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med. 1984;

311:354358.

592. Klein SA, Dobmeyer JM, Dobmeyer TS, et al. Demonstration of the Th1 to Th2 cytokine shift during the course of HIV-1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry. AIDS.

1997;

11:1111 593. Klotman ME, Kim S, Buchbinder A, et al. Kinetics of expression of multiply spliced RNA in early human immunodeficiency virus type 1 infection of lymphocytes and monocytes. Proc Natl Acad Sci U S A.

1991;

88: 594. Knobel H, Miro JM, De-Miguel V, et al. Efficacy of a Short-Term Prednisone Regimen in Nevirapine Associated Rash Prevention: A Double-Blind Placebo-Controlled Clincal Trial. Results of the GESIDA 09/ Study. Abstract L-15. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 17-20, 2000;

Toronto.

595. Koblin BA, McCusker J, Lewis BF, et al. Racial/ethnic differences in HIV-1 seroprevalence and risky behaviors among intravenous drug users in a multisite study. Am J Epidemiol. 1990;

132:837 596. Koebner H. Kranken Vorstellung (idiopathisches multiples sarcoma Hemorrhagicum der Extremitaten). Arch Dermatol Syph (Berl) 1909;

94:121.

597. Koenig S, Earl P, Powell D, et al. Group-specific, major histocompatibility complex class Irestricted cytotoxic responses to human immunodeficiency virus 1 (HIV-1) envelope proteins by cloned peripheral blood T cells from an HIV-1infected individual. Proc Natl Acad Sci U S A. 1988;

85:86388642.

598. Koenig S, Fuerst TR, Wood LV, et al. Mapping the fine specificity of a cytolytic T cell response to HIV-1 nef protein. J Immunol. 1990;

145:127135.

599. Koenig S, Gendelman HE, Orenstein JM, et al. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science. 1986;

233:10891093.

600. Koga Y, Lindstrom E, Fenyo EM, et al. High levels of heterodisperse RNAs accumulate in T cells infected with human immunodeficiency virus and in normal thymocytes. Proc Natl Acad Sci U S A. 1988;

85:4521 4525.

601. Koga Y, Sasaki M, Yoshida H, et al. Cytopathic effect determined by the amount of CD4 molecules in human cell lines expressing envelope glycoprotein of HIV. J Immunol. 1990;

144:94102.

602. Kopp JB, Miller KD, Mican JA, et al. Crystalluria and urinary tract abnormalities associated with indinavir.

Ann Intern Med. 1997;

127:119125.

603. Korber B, Muldoon M, Theiler J, et al. Timing the ancestor of the HIV-1 pandemic strains. Science 2000;

288: 1789-96.

604. Korber B, Theiler J, Wolinsky S. Limitations of a molecular clock applied to considerations of the origin of HIV-1. Science. 1998;

280:1868.

605. Kotler DP. Wasting syndrome: Nutritional support in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1994;

10:931934.

606. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994;

68:46504655.

607. Koup RA, Sullivan JL, Levine PH, et al. Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera. J Virol. 1989;

63:584 590.

608. Koup RA, Sullivan JL, Levine PH, et al. Detection of major histocompatibility complex class Irestricted, HIV-specific cytotoxic T lymphocytes in the blood of infected hemophiliacs. Blood. 1989;

73:19091914.

609. Kovacs J, Lance H, Masur H, et al. A phase III, placebo-controlled trial of recombinant alpha-interferon in asymptomatic individuals seropositive for the acquired immunodeficiency syndrome. Clin Res.

1987;

35:479A.

610. Kovacs JA, Hiemenz JW, Macher AM, et al. Pneumocystis carinii pneumonia: A comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med. 1984;

100:663671.

611. Kovacs JA, Ng VL, Leoung G, et al. Diagnosis of Pneumocystis pneumonia: Improved detection in sputum with use of monoclonal antibodies. N Engl J Med. 1988;

318:589593.

612. Kovacs JA, O'Neill D, Feuerstein I, et al. Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. Lancet. 1992;

340:637638.

613. Kral AH, Bluthenthal RN, Booth RE, Watters JK. HIV seroprevalence among street-recruited injection drug and crack cocaine users in 16 US municipalities. Am J Public Health. 1998;

88:108113.

614. Kreiss KJ, Coombs R, Plummer F, et al. Isolation of human immunodeficiency virus from genital ulcers in Nairobi prostitutes. J Infect Dis. 1989;

160:380384.

615. Kristal A, Nasca P, Burnett W, Mikl J. Changes in the epidemiology of non-Hodgkin's lymphoma associated with epidemic human immunodeficiency virus (HIV) infection. Am J Epidemiol. 1988;

128:711718.

616. Krivine A, Firtion G, Cao L, et al. HIV replication during the first weeks of life. Lancet. 1992;

339:1187 1189.

617. Krown S. The role of interferon in the therapy of epidemic Kaposi's sarcoma. Semin Oncol. 1987;

14(Suppl 3):2733.

618. Kuhn L, Steketee RW, Weedon J, et al. Distinct risk factors for intrauterine and intrapartum human immunodeficiency virus transmission and consequences for disease progression in infected children. J Infect Dis. 1999;

179:52 619. Kuiken CL, Foley B, Hahn B, Korber B, McCutchan F, Marx PA, et al, eds. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM.

620. Kuritzkes DR, Marschner IC, Johnson VA, et al. A randomized, double-blind, placebo-controlled trial of lamivudine (3TC) in combination with zidovudine (ZDV), stavudine (d4T), or didanosine (ddI) in treatment naive patients. Abstract 1. In: 5th Conference on Retroviruses and Opportunistic Infections. Chicago;

1998:79.

621. Lackritz EM, Satten GA, Aberle-Grasse J, et al. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med. 1995;

333:17211725.

622. Lackritz EM, Satten GA, Aberle-Grasse J, et al. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med. 1995;

333:1721 623. Ladman R, Peytavin G, Descamps D, Brun Vezinet F, Benech H, Benalischerif A, Trylesinski A, Katlama C, Girard PM, Raffi F, Yeni P, Bentata M, Jarrousee B, Michelet C, Flandre P, and Tonus Study Group. Low genetic barrier to resistance is a possible cause of early virologic failures in once-daily regimen of abacavir, lamivudine, and tenofavir: The tonus study. 11th Conference on Retroviruses and Opportunistic Infections;

San Francisco;

February 8-11, 2004. Abstract 52.

624. Lafrenie RM, Wahl LM, Epstein JS, et al. HIV-1Tat protein promotes chemotaxis and invasive behavior by monocytes. J Immunol. 1996;

157:974977.

625. Laga M, Manoka A, Kivuvu M, et al. Non-ulcerative sexually transmitted diseases as risk factor for HIV- transmission in women: Results from a cohort study. AIDS. 1993;

7:95102.

626. Laga M, Taelman H, Van der Stuyft P, et al. Advanced immunodeficiency as a risk factor for heterosexual transmission of HIV. AIDS. 1989;

3:361366.

627. Lamptey PR, Kamenga MC, Weir SS. Prevention of sexual transmission of HIV in sub-Saharan Africa:

Lessons learned. In: Laga M, ed. AIDS in Africa, 2nd ed. London: Rapid Science Publishers;

1997:6377.

628. Landis SE, Schoenbach VJ, Weber DJ, et al. Results of a randomized trial of partner notification in cases of HIV infection in North Carolina. N Engl J Med. 1992;

326:101106.

629. Landman, R, Peytavin G, Descamps D, Brun Vezinet F, Benech H, Benalisherif A, Trylesinski A, Katlama C, Girard PM, Raffi F, Yeni P, Bentata M, Jarrousse B, Michelet C, Flandre P, and the Tonus Study Group. 11th Conference on Retroviruses and Opportunistic Infections. February 8-11, 2004. San Francisco. Abstract 52.

630. Lane H, Feinberg J, Davery V, et al. Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma. Lancet. 1988;

2:12181222.

631. Lange WR, Synder FR, Lozovsky D, et al. The geographic distribution of human immunodeficiency virus markers in parenteral drug abusers. Am J Public Health. 1988;

78:443 632. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science. 1995;

269:696699.

633. Lathey JL, Pratt RD, Spector SA. Appearance of autologous neutralizing antibody correlates with reduction in virus load and phenotype switch during primary infection with human immunodeficiency virus type I. J Infect Dis. 1997;

175: 231232.

634. Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, Schmid P, Condreay LD, Gauthier J, Kuhns MC, Liang TJ, Hoofnagle JH. Long-term therapy of chronic hepatitis B with lamivudine.

Hepatology 2000;

32:828-34.

635. Laurence J, Hodtsev AS, Posnett DN. Superantigen implicated in dependence of HIV-1 replication in T cells on TCR V beta expression. Nature. 1992;

358:255 636. Laurent-Crawford AG, Krust B, Muller S, et al. The cytopathic effect of HIV is associated with apoptosis.

Virology. 1991;

185:829 637. Lazzarin A, Saracco A, Musicco M, et al. Man-to-woman sexual transmission of the human immunodeficiency virus. Risk factors related to sexual behavior, man's infectiousness, and woman's susceptibility. Arch Intern Med. 1991;

151:24112416.

638. Lazzarin A, Saracco A, Musicco M, et al. Man-to-woman sexual transmission of the human immunodeficiency virus. Risk factors related to sexual behavior, man's infectiousness, and woman's susceptibility. Arch Intern Med. 1991;

151:2411 639. Learmont J, Tindall B, Evans L, et al. Long-term symptomless HIV-1 infection in recipients of blood products from a single donor. Lancet. 1992;

340:863867.

640. Lecuit M, Oksenhendler E, Sarfati C. Use of albendazole for disseminated microsporidian infection in a patient with AIDS. Clin Infect Dis. 1994;

19:332.

641. Lee BL, Medina I, Benowitz NL, et al. Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS):

Evidence of drug interactions. Ann Intern Med. 1989;

110:606611.

642. Lefrere J-J, Roudot-Thoraval F, Mariotti M. The risk of disease progression is determined during the first year of human immunodeficiency virus type 1 infection. J Infect Dis. 1998;

177:15411548.

643. Lemp GF, Payne SF, Temelso DN, et al. Survival trends for patients with AIDS. JAMA. 1990;

264:402405.

644. Leonard R, Zagury D, Desportes I, et al. Cytopathic effect of human immunodeficiency virus in T4 cells is linked to the last stage of virus infection. Proc Natl Acad Sci U S A. 1988;

85:335703574.

645. Leoung G, Stanford J, Giordano M, et al. A randomized, double-blind trial of TMP/SMX dose escalation vs.

direct rechallenge in HIV+ persons at risk for PCP and with prior treatment-limiting rash or fever. Abstract No. LB-10. In: Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, September 28October 1, 1997.

646. Leoung GS, Feigal DW Jr, Montgomery AB, et al. Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumoniathe San Francisco Community Prophylaxis Trial. N Engl J Med.

1990;

323:769775.

647. Levine A. Acquired immunodeficiency syndromerelated lymphoma. Blood. 1992;

80:8.

648. Levine B, Chaisson RE. Mycobacterium kansasii: A cause of treatable pulmonary disease associated with advanced human immunodeficiency virus (HIV) infection. Ann Intern Med. 1991;

114:861868.

649. Levine WC, Revallo R, Kaune V, et al. Decline in sexually transmitted disease prevalence in female Bolivian sex workers: Impact of an HIV prevention project. AIDS. 1998;

12:18991906.

650. Levy J, Hoffman A, Kramer S, et al. Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science. 1984;

225:840842.

651. Levy JA, Greenspan D. HIV in saliva (Letter). Lancet. 1988;

2:1248.

652. Levy JA, Shimabukuro J, Hollander H, et al. Isolation of AIDS-associated retroviruses from cerebrospinal fluid and brain of patients with neurological symptoms. Lancet. 1985;

2:586588.

653. Levy JA, Shimabukuro J, Hollander H, et al. Isolation of AIDS-associated retroviruses from cerebrospinal fluid and brain of patients with neurological symptoms. Lancet. 1985;

2:586588.

654. Levy RM, Bredesen DE, Rosenblum ML. Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): Experience at UCSF and review of the literature. J Neurosurg. 1985;

62:475495.

655. Lewis SH, Reynolds-Kohler C, Fox HE, et al. HIV-1 in trophoblastic and villous Hofbauer cells, and haematological precursors in eight-week fetuses. Lancet. 1990;

335:565568.

656. Li CJ, Friedman DJ, Wang C, et al. Induction of apoptosis in uninfected lymphocytes by HIV-1 tat protein.

Science. 1995;

268:429431.

657. Lieberman J, Fabry JA, Kuo MC, et al. Cytotoxic T lymphocytes from HIV-1 seropositive individuals recognize immunodominant epitopes in Gp160 and reverse transcriptase. J Immunol. 1992;

148:27382747.

658. Lifson JD, Feinberg MB, Reyes GR, et al. Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein. Nature. 1986;

323:725 659. Lifson JD, Reyes GR, McGrath MS, et al. AIDS retrovirus induced cytopathology: Giant cell formation and involvement of CD4 antigen. Science. 1986;

232:1123 660. Little SJ. Transmission and prevalence of HIV resistance among treatment-naive subjects. Antivir Ther 2000;

5:33-40.

661. Liu Z, Hultin LE, Cumberland WG, et al. Elevated relative fluorescence intensity of CD38 antigen expression on CD8+ T cells is a marker of poor prognosis in HIV infection: Results of 6 years of follow-up. Cytometry.

1996;

26:17.

662. Lori F, Malykh A, Cara A, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type replication. Science. 1994;

266:801.

663. Lori F, Malykh A, Cara A, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type replication. Science. 1994;

266:801805.

664. Louie M, Hurley A, Sun E, Brun S, Ho D, Markowitz M, McGowan I, Ramratnam B, Simon V, Ruiz N. A Regimen containing lopinavir/ritonavir, efavirenz, tenofovir DF, and lamivudine is well-tolerated and more potent than standard HAART. 1st IAS Conference on HIV Pathogenesis and Treatment;

July 8-11, 2001;

Buenos Aires. Abstract 218.

665. Lucey DR, Pinto LA, Bethke FR, et al. In vitro immunologic and virologic effects of interleukin 15 on peripheral blood mononuclear cells from normal donors and human immunodeficiency virus type 1infected patients. Clin Diagn Lab Immunol. 1997;

4:43 666. Lucia B, Jennings C, Cauda R, et al. Evidence of a selective depletion of a CD16+ CD56+ CD8+ natural killer cell subset during HIV infection. Cytometry. 1995;

22:1015.

667. Luft BJ, Hafner R, Korzun AH. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1993;

329:9951000.

668. Lundgren JD, Barton SE, Lazzarin A, et al. Factors associated with the development of Pneumocystis carinii pneumonia in 5,025 European patients with AIDS. Clin Infect Dis. 1995;

21:106113.

669. Lundgren JD, Barton SE, Lazzarin A, et al. Factors associated with the development of Pneumocystis carinii pneumonia in 5,025 European patients with AIDS. Clin Infect Dis. 1995;

21:106113.

670. Lyerly HK, Matthews TJ, Langlois AJ, et al. Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack. Proc Natl Acad Sci U S A. 1987;

84:46014605.

671. Lynn WS, Tweedale A, Cloyd MW. Human immunodeficiency virus (HIV-1) cytotoxicity: Perturbation of the cell membrane and depression of phospholipid synthesis. Virology. 1988;

163:4351.

672. Lyter DW, Bryant J, Thackeray R, et al. Incidence of human immunodeficiency virusrelated and nonrelated malignancies in a large cohort of homosexual men. J Clin Oncol. 1995;

13:25402546.

673. Macallan DC, Noble C, Baldwin C, et al. Energy expenditure and wasting in human immunodeficiency virus infection. N Engl J Med. 1995;

333:8388.

674. Macatonia SE, Lau R, Patterson S, et al. Dendritic cell infection, depletion and dysfunction in HIV-infected individuals. Immunology. 1990;

71:3845.

675. Maciaszek J, Parada N, Cruikshank W, et al. IL-16 represses HIV-1 promoter activity. J Immunol.

1997;

158:58.

676. Mackewicz C, Balckbourn DJ, Levy JA. CD8+ T cells suppress human immunodeficiency virus replication by inhibiting viral transcription. Proc Natl Acad Sci U S A. 1995;

92:23082312.

677. MacMahon E, Glass J, Hayward S, et al. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet. 1991;

338:969.

678. Maddon PJ, Dalgleish AG, McDougal JS, et al. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell. 1986;

47:333348.

679. Maenza JR, Keruly JC, Moore RD, et al. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virusinfected patients. Clin Infect Dis. 1996;

173: 680. Maggi E, Mazzetti M, Ravina A, et al. Ability of HIV to promote a TH1 to TH0 shift and to replicate preferentially in TH2 and TH0 cells. Science. 1994;

265: 244248.

681. Magura S, Grossman JI, Lipton DS, et al. Determinants of needle sharing among intravenous drug users. Am J Public Health. 1989;

79:459462.

682. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen FT. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002 Mar 2;

359(9308):727-32.

683. Mallory DL, Parrillo JE, Bailey KR, et al. Cardiovascular effects and safety of intravenous and intramuscular pentamidine isethionate. Crit Care Med. 1987;

15:503505.

684. Manca F, Habeshaw JA, Dalgleish AG. HIV envelope glycoprotein, antigen specific T-cell responses, and soluble CD4. Lancet. 1990;

335:811815.

685. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al. for the Agence Nationale de Recherches sur le SIDA (ANRS) 075 Study Group. Lamivudine-Zidovudine Combination for Prevention of Maternal-Infant Transmission of HIV-1. JAMA. 2001;

285(16);

2083-2093.

686. Marcus R, Culver DH, Bell DM, et al. Risk of human immunodeficiency virus infection among emergency department workers. Am J Med. 1993;

94:363370.

687. Marder K, Liu X, Stern Y, et al. Neurologic signs and symptoms in a cohort of homosexual men followed for 4.5 years. Neurology. 1995;

45:261267.

688. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med. 1995;

333:15341539.

689. Marks G, Richardson JL, Maldonado N. Self-disclosure of HIV infection to sexual partners. Am J Public Health. 1991;

81:13211323.

690. Marshall DW, Brey RL, Cahill WT, et al. Spectrum of cerebrospinal fluid findings in various stages of human immunodeficiency virus infection. Arch Neurol. 1988;

45:954958.

691. Marshall DW, Brey RL, Cahill WT, et al. Spectrum of cerebrospinal fluid findings in various stages of human immunodeficiency virus infection. Arch Neurol. 1988;

45:954958.

692. Martinez E, Miro JM, Gonzalez J, et al. Withdrawal of Mycobacterium avium complex suppressive therapy in HIV-1 infected patients on highly active antiretroviral therapy. AIDS. 1999;

13:147148.

693. Masur H, et al. Consensus statement on the use of corticosteroids as adjunctive therapy for pneumocystis pneumonia in the acquired immunodeficiency syndrome. N Engl J Med. 1990;

323:15001504.

694. Masur H, Michelis MA, Greene JB, et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: Initial manifestations of cellular immune dysfunction. N Engl J Med. 1981;

305:1431.

695. Masur H, Ognibene FP, Yarchoan R, et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Intern Med. 1992;

111:223231.

696. Masur H, Polis MA, Tuazon CU, et al. Salvage trial of trimetrexate-leucovorin for the treatment of cerebral toxoplasmosis in patients with AIDS. J Infect Dis. 1993;

167:14221426.

697. Masur H. Prevention and treatment of Pneumocystis pneumonia. N Engl J Med. 1992;

327:18531860.

698. Mathews C, Barba D, Fullerton SC. Early biopsy versus empiric treatment with delayed biopsy of non responders in suspected HIV associated cerebral toxoplasmosis: A decision analysis. AIDS. 1995;

9:1243.

699. Matthews TJ, Langlois AJ, Robey WG, et al. Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein. Proc Natl Acad Sci U S A.

1986;

83:97099713.

700. Mayeux R, Tang M, Tocad G, et al. Mortality risks in gay men with human immunodeficiency virus infection and cognitive impairment. Neurology. 1993;

43:176182.

701. Mazza DS, Grieco MH, Reddy MM, et al. Serum IgE in patients with human immunodeficiency virus infection. Ann Allergy Asthma Immunol. 1995;

74: 411414.

702. McArthur JC, Cohen BA, Farzadegan H. Cerebrospinal fluid abnormalities in homosexual men with and without neuropsychiatric findings. Ann Neurol. 1988;

23:S34S37.

703. McArthur JC, Cohen BA, Farzadegan H. Cerebrospinal fluid abnormalities in homosexual men with and without neuropsychiatric findings. Ann Neurol. 1988;

23:S34S37.

704. McCusker J, Koblin B, Lewis BF, et al. Demographic characteristics, risk behaviors, and HIV seroprevalence among intravenous drug users by site of contact: Results from a communitywide HIV surveillance project.

Am J Public Health. 1990;

80:1062 705. McDonald CK, Kuritzkes DR. Human immunodeficiency virus type 1 protease inhibitors. Arch Intern Med.

1997;

157:951959.

706. McNeil C. HIV infection with Hodgkin's disease: The virus makes a difference (News). J Natl Cancer Inst.

1997;

89:754755.

707. Medina I, Mills J, Leoung G, et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndromea controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim dapsone. N Engl J Med. 1990;

323:776782.

708. Melbye M, Grossman RJ, Goedert JJ, et al. Risk of AIDS after herpes zoster. Lancet. 1987:728731.

709. Melbye M, Rabkin C, Frisch M, Biggar RJ. Changing patterns of anal cancer incidence in the United States, 19401989. Am J Epidemiol. 1994;

139:772780.

710. Mellors J, Lederman M, Haas D, et al. Antiretroviral effects of therapy combining abacavir (1592) with HIV protease inhibitors (PIs). Abstract 4. In: 5th Conference on Retroviruses and Opportunistic Infections.

Chicago;

1998:79.

711. Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med. 1995;

122:573579.

712. Mellors JW, Muoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;

126:946954.

713. Mellors JW, Rinaldo CR, Phalguni G, et al. Prognosis in HIV-1 infection predicted by quantity of virus in plasma. Science. 1996;

272:11671170.

714. Meng TC, Fischl MA, Boota AM, et al. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study. Ann Intern Med.

1992;

116:13 715. Merck Research Laboratories. Letter to investigators. April 8, 1998.

716. Merrill DP, Moonis M, Chou TC, Hirsch MS. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. J Infect Dis. 1996;

173:355364.

717. Merry C, Barry MG, Mulcahy F, et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS. 1997;

11:F29F33.

718. Meyaard L, Otto S, Keet I, vanLier R, et al. Changes in cytokine secretion patterns of CD4+ T-cell clones in human immunodeficiency virus infection. Blood. 1994;

84:4262 719. Meyaard L, Otto SA, Jonker RR, et al. Programmed death of T cells in HIV-1 infection. Science.

1992;

257:217 720. Meyaard L, Otto SA, Keet IP, et al. Programmed death of T cells in human immunodeficiency virus infection. No correlation with progression to disease. J Clin Invest. 1994;

93:982988.

721. Meyaard L, Schuitemaker H, Miedema F. T-cell dysfunction in HIV infection: Anergy due to defective antigen-presenting cell function? Immunol Today. 1993;

14:161 722. Meyers G, Berzofsky JA, Korber B, et al. Human Retroviruses and AIDS. Los Alamos National Laboratory, New Mexico, 1992.

723. Michael N, Chang G, Louie L, et al. The role of viral phenotype and CCR-5 gene defects in HIV- transmission and disease progression. Nat Med. 1997;

3:338340.

724. Michael NL, Chang G, D'arcy LA, et al. Defective accessory genes in a human immunodeficiency virus type 1infected long-term survivor lacking recoverable virus. J Virol. 1995;

69:42284236.

725. Michael NL, Chang G, D'arcy LA, et al. Functional characterization of human immunodeficiency virus type nef genes in patients with divergent rates of disease progression. J Virol. 1995;

69:67586769.

726. Michael NL, Nelson JA, KewalRamani VN, et al. Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32. J Virol.

1998;

72:6040 727. Michael NL, Vahey M, Burke RS, et al. Viral DNA and mRNA expression correlate with the stage of human immunodeficiency virus (HIV) type 1 infection in humans: Evidence for viral replication in all stages of HIV disease. J Virol. 1992;

66:310316.

728. Miedema F. Immunological abnormalities in the natural history of HIV infection: Mechanisms and clinical relevance. Immunodefic Rev. 1992;

3:173193.

729. Miles SA. Pathogenesis of AIDS-related Kaposi's sarcoma. Evidence of a viral etiology. Hematol Oncol Clin North Am. 1996;

10:10111021.

730. Miller MD, Margot N, Coakley D, Cheng A. Anti-HIV responses and development of RT mutations in antiretroviral-experienced patients adding tenofovir DF (TDF) therapy: Baseline and Week 24 genotypic analyses of Study 907. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy;

December 16-19, 2001;

Chicago. Abstract 1928.

731. Miller MD, Margot NA, Hertogs K, Larder B, Miller V. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples. Nucleosides Nucleotides Nucleic Acids 2001;


20:1025-8.

732. Miller MD, Margot NA, Lamy PD, Fuller MD, Anton KE, Mulato AS, Cherrington JM. Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408. J Acquir Immune Defic Syndr 2001;

27:450-8.

733. Miller MD, Margot NA, Lu B. Effect of baseline nucleoside-associated resistance on response to tenofovir DF (TDF) therapy: Integrated analyses of studies 902 and 907. 9th Conference on Retroviruses and Opportunistic Infections. February 24-28, 2002;

Seattle. Abstract 43.

734. Mills J, Leoung G, Medina J, et al. Dapsone treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Antimicrob Agents Chemother. 1988;

32:10571060.

735. Mitsuya H, Weinhold KJ, Furman PA, et al. 3-Azido-2-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy associated virus in vitro. Proc Natl Acad Sci U S A. 1985;

82:7096.

736. Mitsuyasu R, Groopman J. Biology and therapy of Kaposi's sarcoma. Semin Oncol. 1984;

11:5359.

737. Mitsuyasu RT, Skolnik PR, Cohen SR, et al. Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. NV15355 Study Team. AIDS. 1998;

12:F103F109.

738. Mizusawa H, Hirano A, Llena JF, Shintaku M. Cerebrovascular lesions in acquired immune deficiency syndrome (AIDS). Acta Neuropathol. 1988;

76:451457.

739. MMWR (a) Morb Mortal Wkly Rep. 1992;

41(RR17):119.

740. MMWR (b) Morb Mortal Wkly Rep. 1992;

42(RR17) 741. Mocroft A, Bofill M, Lipman M, et al. CD8+, CD38+ lymphocyte percent: A useful immunological marker for monitoring HIV-1infected patients. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;

14:158162.

742. Molina JM, Ferchal F, Rancinan C, Yeni P, Rozenbaum W, Journot V, Morand-Joubert L, Fournier S, Morlat P, Dupont B, Delfraissy JF, Dellamonica P, Poizot-Martin I, Rosenthal E, Chene G. Once-daily Combination of Emtricitabine, Didanosine, and Efavirenz vs Continued PI-based HAART in HIV-infected Adults with Undetectable Plasma HIV-RNA: 48-week Results of a Prospective Randomized Multicenter Trial (ALIZE ANRS 99). 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 10-14, 2003. Abstract 551.

743. Molina JM, Goguel J, Sarfati C, et al. Drug screening for treatment of Enterocytozoon bieneusi infections in patients with HIV infection (ANRS 034). Abstract No. 687. In: Abstracts of the Fourth International Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 2226, 1996.

744. Molina JM, Oksenhendler E, Beauvais B, et al. Disseminated microsporidiosis due to Septata intestinalis in patients with AIDS: Clinical features and response to albendazole therapy. J Infect Dis. 1995;

171:245.

745. Monini P, de Lellis L, Fabris M, et al. Kaposi's sarcomaassociated herpesvirus DNA sequences in prostate tissue and human semen. N Engl J Med. 1996;

334:11681172.

746. Montagnier L. Virus. New York: Norton, 2000.

747. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA. 1998;

279:930937.

748. Montaner JS, Zala C, Conway B, et al. A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080. J Infect Dis. 1997;

175:801806.

749. Montaner JSG, Lawson LM, Gervais A, et al. Aerosol pentamidine for secondary prophylaxis of AIDS related Pneumocystis carinii pneumonia: A randomized, placebo-controlled study. Ann Intern Med.

1991;

114:948953.

750. Montefiori DC, Pantaleo G, Fink LM, et al. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis. 1996;

173:6067.

751. Moore RD, Hidalgo J, Sugland B, et al. Zidovudine and the natural history of the acquired immunodeficiency syndrome. N Engl J Med. 1991;

324:14121416.

752. Moorman A, Von Bargen J, Palella F, et al. Determinants of breakthrough Pneumocystis carinii pneumonia (PCP) in the HIV outpatient study (HOPS). Abstract No. 294. In: Abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections, American Society of Microbiology, Washington, DC;

January 22 26, 1997.

753. Morgello S, Block GA, Price RW, Petito CK. Varicella-zoster virus leukoencephalitis and cerebral vasculopathy. Arch Pathol Lab Med. 1988;

112:173177.

754. Morris JT, Kelly JW. Effective treatment of cerebral toxoplasmosis with doxycycline. Am J Med.

1992;

93:107.

755. Moses S, Plummer FA, Ngugi E, et al. Controlling HIV in Africa: Effectiveness and cost of an intervention in a high-frequency STD transmitter core group. AIDS. 1991;

5:407411. 73. Laga M, Alary M, Nzila N, et al.

Condom promotion and STD treatment, and declining incidence of HIV-1 infection in female Zairian sex workers. Lancet. 1994;

344:24462448.

756. Moss AR, Bacchetti P, Osmond D, et al. Seropositivity for HIV and the development of AIDS or AIDS related condition: Three year follow up of the San Francisco General Hospital Cohort. BMJ. 1988;

296:745 750.

757. Moss AR, Osmond D, Bacchetti P, et al. Risk factors for AIDS and HIV seropositivity in homosexual men.

Am J Epidemiol. 1987;

125:10351047.

758. Moss GB, Overbaugh J, Welch M, et al. Human immunodeficiency virus DNA in urethral secretions in men:

Association with gonococcal urethritis and CD4 depletion. J Infect Dis. 1995;

172:1469 759. Moss PA, Rowland-Jones SL, Frodsham PM, et al. Persistent high frequency of human immunodeficiency virusspecific cytotoxic T cells in peripheral blood of infected donors. Proc Natl Acad Sci U S A.

1995;

92:57735777.

760. Moyle G, Maitland D, Hand J, Mandalia S, Nelson M, Gazzard B. Early virological failure in persons with viral loads 100,000 cps/ml and CD4 counts 200 cells/mm receiving ddI/tenofovir/efavirenz as initial therapy: results from a randomized comparative trial. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy;

October 30 - November 2, 2004;

Washington, DC. Abstract H-566.

761. Moyle G, Maitland D, Hand J, Mandalia S, Nelson M, Gazzard B. Early virological failure in persons with viral loads 100,000 cps/ml and CD4 counts 200 cells/mm receiving ddI/tenofovir/efavirenz as initial therapy: results from a randomized comparative trial. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy;

October 30-November 2, 2004;

Washington, DC. Abstract H-566.

762. Moyle G, Pozniak A, Opravil M, Clumeck N, DelFraissy JF, Johnson M, Pelgrom J, Reynes J, Vittecoq D, DeLora P, Salgo M, Duff F. The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. Study of Protease Inhibitor Combinations in Europe. J Acquir Immune Defic Syndr 2000;

23:128-37.

763. Moyle G. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther 2000;

22:911-36;

discussion 898.

764. Moyle G. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther 2000;

22:911-36;

discussion 765. Moyle G. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther 2000;

22:911-36;

discussion 898.

766. Moyle G. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther. 2000 Aug;

22(8):911-36;

discussion 898.

767. Muller F, Rollag H, Froland SS. Reduced oxidative burst responses in monocytes and monocyte-derived macrophages from HIV-infected individuals. Clin Immunol Immunopathol. 1990;

82:1015.

768. Muller H, Weier S, Kojouharoff G, et al. Distribution and infection of Langerhans cells in the skin of HIV infected healthy subjects and AIDS patients. Res Virol. 1993;

144:59 769. Mummaneni V, Randall D, Chabuel D, Geraldes M, O'Mara E. Steady-State Pharmacokinetic (PK) Interaction Study of Atazanavir (ATV) with Clarithromycin (CLR) in Healthy Subjects. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September 27-30, 2002, Abstract H1717.

770. Muoz A, Schrager L, Bacellar H, et al. Trends in the incidence of outcomes defining acquired immunodeficiency syndrome (AIDS) in the Multicenter AIDS Cohort Study: 19851991. Am J Epidemiol.

1993;

137:423438.

771. Murayama T, Cai Q, Rinaldo CR. Antibody-dependent cellular cytotoxicity mediated by CD16+ lymphocytes from HIV-seropositive homosexual men. Clin Immunol Immunopathol. 1990;

55:297304.

772. Muro-Cacho CA, Pantaleo G, Fauci AS. Analysis of apoptosis in lymph nodes of HIV-infected persons. J Immunol. 1995;

154:5555 773. Murphy RL, Gulick RM, DeGruttola V, et al. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. J Infect Dis.

1999;

179:808816.

774. Murphy RL, Lavelle JP, Allan JD, et al. Aerosol pentamidine prophylaxis following Pneumocystis carinii pneumonia in AIDS patients: Results of a blinded dose-comparison study using an ultrasonic nebulizer. Am J Med. 1991;

90:418426.

775. Murray HW, Godbold JH, Jurica KB, Roberts RB. Progression to AIDS in patients with lymphadenopathy or AIDS-related complex: Reappraisal of risk and predictive factors. Am J Med. 1989;


86:533538.

776. Murray HW, Godbold JH, Jurica KB, Roberts RB. Progression to AIDS in patients with lymphadenopathy or AIDS-related complex: Reappraisal of risk and predictive factors. Am J Med. 1989;

86:533538.

777. Musey L, Hughes J, Schacker T, et al. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med. 1997;

337:12671274.

778. Musicco M, Lazzarin A, Nicolasi A, et al. Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission: Italian Study Group on HIV Heterosexual Transmission. Arch Intern Med. 1994;

154:19711976.

779. Muster T, Steindl F, Purtscher M, et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol. 1993;

67:66426647.

780. Nabel G, Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature. 1987;

326:711.

781. Naif HM, Li S, Ho-Shon M, et al. The state of maturation of monocytes into macrophages determines the effects of IL-4 and IL-13 on HIV replication. J Immunol. 1997;

158:501511.

782. Naimi N, Plancherel C, Bosser C, et al. Anticardiolipin antibodies in HIV-negative and HIV-positive hemophiliacs. Blood Coagul Fibrinolysis. 1990;

1:58.

783. Nakagawa M, Maruyama Y, Sugita H, Osame M. Nationwide survey of neurologic manifestations of acquired immunodeficiency syndrome in Japan. Intern Med. 1997;

36:175178.

784. Nasr S, Brynes R, Garrison C, Chan W. Peripheral T-cell lymphoma in a patient with acquired immunodeficiency syndrome. Cancer. 1988;

61:947951.

785. National Commission on AIDS. Behavioral and social sciences and the HIV/AIDS epidemic. National Commission on AIDS, Washington, DC, 786. Navia BA, Cho E-S, Petito CK, Price RW. The AIDS dementia complex: II. Neuropathology. Ann Neurol.

1986;

19:525535.

787. Navia BA, Jordan BD, Price RW. The AIDS dementia complex: I. Clinical features. Ann Neurol.

1986;

19:517524.

788. Navin TR, Fontaine RE. Intravenous versus intramuscular administration of pentamidine. N Engl J Med.

1984;

311:17011702.

789. Neaigus A, Sufian M, Friedman SR, et al. Effects of outreach intervention on risk reduction among intravenous drug users. AIDS Educ Prev. 1990;

2:253 790. Nelson KE, Celentano DD, Eiumtrakol S, et al. Changes in sexual behavior and a decline in HIV infection among young men in Thailand. N Engl J Med. 1996;

335:297303.

791. Nelson KE, Vlahov D, Cohn S, et al. Sexually transmitted diseases in a population of intravenous drug users:

Association with seropositivity to the human immunodeficiency virus (HIV). J Infect Dis. 1991;

164:457 792. Nelson M, Portsmouth S, Stebbing J, Atkins M, Barr A, Matthews G, Pillay D, Fisher M, Bower M, Gazzard B. An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals. AIDS. 2003 Jan 3;

17(1):F7-F10.

793. Newcomer VD. Human immunodeficiency virus infection and acquired immunodeficiency syndrome in the elderly (Letter). Arch Dermatol. 1997;

133:13111312.

794. Nickoloff B, Foreman K. Charting a new course through the chaos of KS (Kaposi's sarcoma). Am J Pathol.

1996;

148:13231329.

795. Nielsen TL, Eeftinck Schattenkerk JK, Jensen BN, et al. Adjunctive corticosteroid therapy for Pneumocystis carinii pneumonia in AIDS: A randomized European multicenter open label study. J Acquir Immune Defic Syndr. 1992;

5:726731.

796. Nieto-Cisneros L, Zala C, Fessel WJ, Gonzalez-Garcia J, Cohen C, McGovern R, Adler E, McLaren C.

Antiviral Efficacy, Metabolic Changes and Safety of Atazanavir (ATV) Versus Lopinavir/Ritonavir (LPV/RTV) in Combination with 2 NRTIs in Patients Who Have Experienced Virologic Failure with Prior Pi-Containing Regimen(s): 24-Week Results from BM. 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, July 13-16, 2003. Abstract 117.

797. Niu MT, Stein DS, Schnittman SM. Primary human immunodeficiency virus type I infection: Review of pathogenesis and early treatment intervention in human and animal retrovirus infections. J Infect Dis.

1993;

168:14901501.

798. Niwa Y, Yano M, Futaki S, et al. T-cell membraneassociated serine protease, tryptase TL2, binds human immunodeficiency virus type 1 gp120 and cleaves the third-variable-domain loop of gp120. Neutralizing antibodies of human immunodeficiency virus type 1 inhibit cleavage of gp120. Eur J Biochem. 1996;

237:64 70.

799. Nixon DF, Townsend AR, Elvin JG, et al. HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature. 1988;

336:484487.

800. Northfelt DW, Dezube BJ, Thommes JA, et al. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol. 1997;

15:653659.

801. Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: Results of a randomized phase III clinical trial. J Clin Oncol. 1998;

16:24452451.

802. Noskin GA, Murphy RL, Black JR, Phair JP. Salvage therapy with clindamycin/primaquine for Pneumocystis carinii pneumonia. Clin Infect Dis. 1992;

14:183188.

803. Notermans DW, Jurriaans S, de Wolf F, Foudraine NA, de Jong JJ, Cavert W, Schuwirth CM, Kauffmann RH, Meenhorst PL, McDade H, Goodwin C, Leonard JM, Goudsmit J, Danner SA. Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine.

Ritonavir/3TC/ZDV Study Group. AIDS 1998;

12:167-73.

804. Nunez M, Soriano V, Martin-Carbonero L, Rodriguez-Rosado R, Diaz B, Gonzalez-Lahoz J. The SENC trial:

a randomized, open-label study comparing efavirenz versus nevirapine. Results at 48 weeks. The XIV International AIDS Conference, Barcelona, July, 2002. Abstract TuPeB4441.

805. Oberlin E, Amara A, Bachelerie F, et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-lineadapted HIV-1. Nature. 1996;

382:833 806. O'Brien JG, Dong BJ, Coleman RL, et al. A 5-year retrospective review of adverse drug reactions and their risk factors in human immunodeficiency virusinfected patients who were receiving intravenous pentamidine therapy for Pneumocystis carinii pneumonia. Clin Infect Dis. 1997;

24:854859.

807. O'Brien S. AIDS: A role for host genes. Hosp Pract. 1998;

33:53.

808. O'Brien T, Winkler C, Dean M, et al. HIV-1 infection in a man homozygous for CCR5 32. Lancet.

1997;

349: 809. O'Brien TR, Blattner WA, Waters D, et al. Serum HIV-1 RNA levels and time to development of AIDS in the multicenter hemophilia cohort study. JAMA. 1996;

276:105110.

810. O'Brien WA, Grovit-Ferbas K, Namazi A, et al. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood. 1995;

86:10821089.

O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts 811.

and the risk of progression to AIDS. N Engl J Med. 1996;

334:426431.

812. O'Doherty MJ, Thomas S, Page C, et al. Differences in relative efficacy of nebulizers for pentamidine administration. Lancet. 1988;

2:12831286.

813. Ogg G, Jin X, Bonhoeffer S, et al. Quantitation of HIV-1 specific cytotoxic T lymphocytes and plasma load of viral RNA. Science. 1998;

279:21032106.

814. Ognibene FP, Shelhamer J, Gill V, et al. The diagnosis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome using subsegmental bronchoalveolar lavage. Am Rev Respir Dis.1984;

129:933937.

815. Ojo-Amaize EA, Nishanian P, Keith DE, et al. Antibodies to human immunodeficiency virus in human sera induce cell-mediated lysis of human immunodeficiency virusinfected cells. J Immunol. 1987;

139:2458 2463.

816. Oliva A, Kinter AL, Vaccarezza M, et al. Natural killer cells from human immunodeficiency virus (HIV) infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. J Clin Invest. 1998;

102:223231.

817. O'Mara E, Mummaneni V, Bifano M, Randall D, Uderman H, Knox L, Geraldes M. Steady-State Pharmacokinetic Interaction Study Between BMS-232632 and Ritonavir in Healthy Subjects. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, Sept. 4-8, 2001, Abstract 740.

818. Opravil M, Marincek B, Fuchs WA, et al. Shortcomings of chest radiography in detecting Pneumocystis carinii pneumonia. J Acquir Immun Defic Syndr. 1993;

7:3945.

819. O'Riordan TG, Smaldone GC. Exposure of health care workers to aerosolized pentamidine. Chest.

1992;

101:14941499.

820. Osborn L, Kunkel S, Nabel GJ. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc Natl Acad Sci U S A.

1989;

86:2336 821. Osmond D, Chaisson RE, Moss A, et al. Lymphadenopathy in asymptomatic patients seropositive for HIV. N Engl J Med. 1987;

317:246.

822. Oyaizu N, McCloskey TW, Coronesi M, et al. Accelerated apoptosis in peripheral blood mononuclear cells (PBMCs) from human immunodeficiency virus type-1 infected patients and in CD4 cross-linked PBMCs from normal individuals. Blood. 1993;

82:3392 823. Packer SJ, Cesario T, Williams JH Jr. Mycobacterium avium complex infection presenting as endobronchial lesions in immunosuppressed patients. Ann Intern Med. 1988;

109:389393.

824. Padian NS, Shiboski SC, Jewell NP. Female-to-male transmission of human immunodeficiency virus. JAMA.

1991;

266:1664 825. Padian NS, Shiboski SC, Jewell NP. The effect of number of exposures on the risk of heterosexual HIV transmission. J Infect Dis. 1990;

161:883 826. Pakker NG, Kroon EDMB, Roos MTL, et al. Immune restoration does not invariably occur following long term HIV-1 suppression during antiretroviral therapy. AIDS. 1999;

13:203212.

827. Palasithran P, Ziegler JB, Stewart GJ, et al. Breastfeeding during primary human immunodeficiency virus infection and risk of transmission from mother to infant. J Infect Dis. 1993;

167: 828. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;

338:853860.

829. Palker TJ, Clark ME, Langlois AJ, et al. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc Natl Acad Sci U S A. 1988;

85:19321936.

830. Pallesen G, Gerstoft J, Mathiesen L. Stages in LAV/HTLV-III lymphadenitis: I. Histological and immunohistological classification. Scand J Immunol. 1987;

25: 8391.

831. Pantaleo G, Butini L, Graziosi C, et al. Human immunodeficiency virus (HIV) infection in CD4+ T lymphocytes genetically deficient in LFA-1: LFA-1 is required for HIV-mediated cell fusion but not for viral transmission. J Exp Med. 1991;

173:511514.

832. Pantaleo G, Demarest JF, Schacker T, et al. The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci U S A. 1997;

94:254258.

833. Pantaleo G, Demarest JF, Soudeyns H, et al. Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV. Nature. 1994;

370:463467.

834. Pantaleo G, Fauci AS. Immunopathogenesis of HIV infection. Annu Rev Microbiol. 1996;

50:825854.

835. Pantaleo G, Graziosi C, Butini L, et al. Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc Natl Acad Sci U S A. 1991;

88:98389842.

836. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature. 1993;

362:355 837. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature. 1993;

362:355358.

838. Pantaleo G, Menzo S, Vaccarezza M, et al. Studies in subject with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med. 1995;

332:209216.

839. Pape JW, Verdier RI, Boncy M, et al. Cyclospora infection in adults infected with HIV: Clinical manifestations, treatment, and prophylaxis. Ann Intern Med. 1994;

121:654.

840. Pape JW, Verdier RI, Johnson WD Jr. Treatment and prophylaxis of Isospora belli infection in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1989;

320:1044.

841. Para MF, Dohn M, Fram P, et al. ACTG 268 Trialgradual initiation of trimethoprim/sulfamethoxazole (T/S) as primary prophylaxis for Pneumocystis carinii pneumonia (PCP). Abstract No. 2. In: Abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections, American Society of Microbiology, Washington, DC;

January 2226, 1997.

842. Park YD, Belman AL, Kim TS. Stroke in pediatric acquired immunodeficiency syndrome. Adv Neurol.

1990;

28:303311.

843. Pasquier, C., P.Y. Bello, P. Gourney, J. Puel, and J. Izopet. A new generation of serum anti-HIV antibody immunocapture assay for saliva testing. Clin Diag Virol 1997;

8: 195197.

844. Paterson DL, Georghiou PR, Allworth AM, et al. Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection. Clin Infect Dis. 1995;

20;

250254.

845. Paton P, Poly H, Gonnaud P. Acute meningoradiculitis concomitant with seroconversion to human immunodeficiency virus type 1. Res Virol. 1990;

141:427433.

846. Paul DA, Falk LA, Kessler HA, et al. Correlation of serum HIV antigen and antibody with clinical status in HIV-infected patients. J Med Virol. 1987;

22: 357363.

847. Pavia AT, Benyo M, Niler L, et al. Partner notification for control of HIV: Results after 2 years of a statewide program in Utah. Am J Public Health. 1993;

83:14181424.

848. Paxton WA, Martin SR, Tse D, et al. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposures. Nat Med. 1996;

2:412 849. Pedersen C, Katzenstein T, Nielsen C, et al. Prognostic value of serum HIV-RNA levels at virologic steady state after seroconversion: Relation to CD4 cell count and clinical course of primary infection. J Acquir Immun Defic Syndr Hum Retrovirol. 1997;

16:9399.

850. Peeters M. Recombinant HIV sequences: their role in the global epidemic. In: Human retroviruses and AIDS 2000: a compilation and analysis of nucleic acid and amino acid Sequences. Kuiken CL, Foley B, Hahn B, et al, eds. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM 851. Penn I. Cancers of the anogenital region in renal transplant recipients: Analysis of 65 cases. Cancer.

1986;

58:611616.

852. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1 infected compartments during combination therapy. Nature. 1997;

387:188191.

853. Perlman DC, El-Sadr WM, Nelson ET, et al. Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virusrelated immunosuppression. Clin Infect Dis.

1997;

25:242 854. Peterman TA, Lui KJ, Lawrence DN, et al. Estimating the risks of transfusion-associated acquired immune deficiency syndrome and human immunodeficiency virus infection. Transfusion. 1987;

27:371374.

855. Peterman TA, Stoneburner RL, Allen JR, et al. Risk of human immunodeficiency virus transmission from heterosexual adults with transfusion-associated infections. JAMA. 1988;

59:5558.

856. Peters M, Anderson J, Lynch P, Jacobson J, Sherman K, Alston Smith B, Swindells S, Liu T, Johnson V, Pollard R, Rooney J, Polsky B, and AACTG 5127 team. Tenofovir Disoproxil Fumarate Is Not Inferior to Adefovir Dipivoxil for the Treatment of Hepatitis B Virus in Subjects Who Are Co-infected with HIV:

Results of ACTG A5127. 12th Conference on Retroviruses and Opportunistic Infections;

February 22-25, 2005;

Boston. Abstract 124.

857. Petruckevitch A, Del Amo J, Phillips AN, et al. Disease progression and survival following specific AIDS defining conditions: A retrospective cohort study of 2048 HIV-infected persons in London. AIDS.

1998;

12:107113.

858. Phuapradit W. Timing and mechanism of perinatal human immunodeficiency virus-1 infection. Aust N Z J Ostet Gynaecol. 1998;

38:293297.

859. Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med. 1996;

335:384391.

860. Pinto AN. AIDS and cerebrovascular disease. Stroke. 1996;

27:538543.

861. Piot P, Laga M. Genital ulcers, other sexually transmitted diseases, and the sexual transmission of HIV. The first two may be important risk factors for the third. BMJ. 1989;

298:623624.

862. Piscitelli S, Bechtel C, Sadler B, Falloon J. The Addition of a Second Protease Inhibitor Eliminates Amprenavir-Efavirenz Drug Interactions and Increases Plasma Amprenavir Concentrations. Abstract 78. 7th Conference on Retroviruses and Opportunistic Infections. January 30 - February 2, 2000;

San Francisco.

863. Plata F, Autran B, Martins LP, et al. AIDS virusspecific cytotoxic T lymphocytes in lung disorders. Nature.

1987;

328:348351.

864. Plummer FA, Simonsen JN, Cameron DW, et al. Cofactors in male-female sexual transmission of human immunodeficiency virus type 1. J Infect Dis. 1991;

163:233239.

865. Podzamczer D, Ferrer E, Consiglio E, Gatell JM, Perez P, Perez JL, Luna E, Gonzalez A, Pedrol E, Lozano L, Ocana I, Llibre JM, Casiro A, Aranda M, Barrufet P, Martinez-Lacasa J, Miro JM, Badia X, Casado A, Lupo S, Cahn P, Manos M, Estela J. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Antivir Ther. Jun;

7(2):81-90.

866. Podzamczer D, Ferrer E, Gatell JM, et al. Early virological failure and occurrence of resistance in naive patients receiving tenofovir, didanosine and efavirenz. Antivir Ther. 2004;

9:S172.

867. Podzamczer D, Ferrer E, Gatell JM, et al. Early virological failure and occurrence of resistance in naive patients receiving tenofovir, didanosine and efavirenz. Antivir Ther. 2004;

9:S172.

868. Poiesz BJ, Ruscetti FW, Reitz MS, et al. Isolation of a new type-C retrovirus (HTLV) in primary uncultured cells of a patient with Szary T-cell leukaemia. Nature. 1981;

294:2686.

869. Pokrovsky VV, Eramova EU. Nosocomial outbreak of HIV infection in Elista, USSR. Abstract W.A.O.5.

Presented at the Fifth International Conference on AIDS. Montreal, June 49, 1989.



Pages:     | 1 |   ...   | 8 | 9 || 11 |
 
 >>  ()





 
<<     |    
2013 www.libed.ru - -

, .
, , , , 1-2 .